Chroma Medicine, a Cambridge, MA-based genomic medicine company, raised $135M in Series B funding.
The round was led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.
The company intends to use the funds to progress its single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity.
Led by CEO Catherine Stehman-Breen, Chroma Medicine is a biotechnology company providing genomic medicines that harness the cells’ innate mechanism for gene regulation to precisely and durably silence, activate, and multiplex genes using a single platform, without changing the underlying DNA sequence. This approach enables the company to more effectively address a wide range of diseases and to target multiple pathways for complex diseases.
